Fig. 1From: Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trialAlluvial plots of distribution of endotype transitions of patients of the SAVE-MORE trial treated with standard-of-care (SoC) and anakinra (left panel) and standard-of-care (SoC) and placebo (right panel), from baseline endotype to the endotype of days 4 and 7 of treatmentBack to article page